Net Income (Loss) Attributable to Parent in USD of Bolt Biotherapeutics, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Bolt Biotherapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2025.
  • Bolt Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$7.14M, a 52.9% increase year-over-year.
  • Bolt Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$42.7M, a 34.4% increase year-over-year.
  • Bolt Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$63.1M, a 8.79% increase from 2023.
  • Bolt Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$69.2M, a 21.5% increase from 2022.
  • Bolt Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$88.1M, a 10.6% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Bolt Biotherapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$42.7M -$7.14M +$8.03M +52.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 -$50.7M -$8.56M +$12.6M +59.6% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 -$63.3M -$11M -$229K -2.12% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q4 2024 -$63.1M -$15.9M +$1.97M +11% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-24
Q3 2024 -$65.1M -$15.2M +$1.08M +6.65% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 -$66.2M -$21.2M -$3.14M -17.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 -$63M -$10.8M +$6.17M +36.3% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q4 2023 -$69.2M -$17.9M +$2.09M +10.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-24
Q3 2023 -$71.3M -$16.3M +$5.5M +25.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$76.8M -$18.1M +$4.61M +20.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$81.4M -$17M +$6.7M +28.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$88.1M -$20M +$7.16M +26.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$95.3M -$21.8M +$1.64M +6.99% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$96.9M -$22.7M +$921K +3.91% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$97.8M -$23.7M +$776K +3.17% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$98.6M -$27.2M +$3.88M +12.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 -$102M -$23.4M -$13.4M -134% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$89.1M -$23.6M -$12.5M -113% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$76.5M -$24.5M -$15.8M -183% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$60.7M -$31M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$10M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$11.1M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$8.63M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13

Bolt Biotherapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$63.1M +$6.08M +8.79% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-24
2023 -$69.2M +$18.9M +21.5% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-24
2022 -$88.1M +$10.5M +10.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$98.6M -$37.9M -62.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-29
2020 -$60.7M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.